1-[3-(dimethylamino)-propyl]-3-ethylcarbodiimide methiodide | 138551-31-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-[3-(dimethylamino)-propyl]-3-ethylcarbodiimide methiodide
• 英文别名: N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide methyliodide
• CAS: 138551-31-2
• 化学式: CH₃I*C₈H₁₇N₃
• 分子量: 297.182
• InChiKey: ASYVZGDYOMRIPZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.18
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  28
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  碘甲烷 、 1-[3-(dimethylamino)-propyl]-3-ethylcarbodiimide methiodide 生成 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺
  参考文献：
  名称：

  Chemical compounds

  摘要：

  本发明涉及咪唑吡啶衍生物。更具体地，涉及式(I)中的4-(联苯基-3-基)-7H-咪唑[4,5-c]吡啶衍生物及其药学上可接受的盐，其中R1、R2、R3、R4和R5如描述中所定义。本发明的咪唑吡啶衍生物调节GABAA受体的活性。它们在治疗多种疾病，包括疼痛方面具有用途。

  公开号：

  US08952008B2
• 作为产物：
  描述：

  1-乙基-3(3-二甲基氨基)脲 在 三乙胺 、 对甲苯磺酰氯 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 反应 52.0h， 生成 1-[3-(dimethylamino)-propyl]-3-ethylcarbodiimide methiodide
  参考文献：
  名称：

  A new mechanism involving cyclic tautomers for the reaction with nucleophiles of the water-soluble peptide coupling reagent 1-ethyl-3-(3'-(dimethylamino)propyl)carbodiimide (EDC)

  摘要：

  DOI：

  10.1021/ja00414a011
• 作为试剂：
  描述：

  去甲麻黄碱 在 2,6-二甲基吡啶 、 4-二甲氨基吡啶 、 1-[3-(dimethylamino)-propyl]-3-ethylcarbodiimide methiodide 作用下， 以 二氯甲烷 为溶剂， 反应 2.5h， 生成
  参考文献：
  名称：

  Enhanced Diastereoselectivity via Confinement:  Photoisomerization of 2,3-Diphenylcyclopropane-1-carboxylic Acid Derivatives within Zeolites

  摘要：

  From the perspective of asymmetric induction, the photochemistry of 24 chiral esters and amides of cis-2,3-diphenylcyclopropane-1-carboxylic acid from excited singlet and triplet states has been investigated within zeolites. The chiral auxiliaries placed at a remote location from the isomerization site functioned far better within a zeolite than in solution. Generally, chiral auxiliaries with an aromatic or a carbonyl substituent performed better than the ones containing only alkyl substituents. A model based on cation-binding-dependent flexibility of the chiral auxiliary accounts for the observed variation in de between aryl (and carbonyl) and alkyl chiral auxiliaries within zeolites. Cation-dependent diastereomer switch was also observed in select examples.

  DOI：

  10.1021/jo049365i

文献信息

• THIENYLPYRIDYLCARBOXAMIDES
  申请人：Dunkel Ralf

  公开号：US20110105564A1

  公开（公告）日：2011-05-05

  Novel thienylpyridylcarboxamides of the formula (I) The present application is also directed to a plurality of processes for preparing these compounds and their use for controlling unwanted microorganisms, and also novel intermediates and their preparation.

  新型噻吩基吡啶基羧酰胺的化学式（I） 本申请还涉及多种制备这些化合物的方法，以及它们用于控制不受欢迎的微生物的用途，还有新颖的中间体及其制备。
• DIAMINOPROPANE DERIVED MACROCYCLES AS INHIBITORS OF BETA AMYLOID PRODUCTION
  申请人：Marcin Lawrence R.

  公开号：US20080194535A1

  公开（公告）日：2008-08-14

  There is provided a series of macrocyclic diaminopropanes of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , m, n, W, X, Y, Z and L as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

  提供一系列宏环脂肪二胺丙烷化合物的化学式（I）或其立体异构体；或其药用盐， 其中R1，R2，R3，m，n，W，X，Y，Z和L如本文所定义，它们的药物组合物和使用方法。这些新化合物抑制β-分泌酶对淀粉样前体蛋白（APP）的加工，更具体地说，抑制Aβ-肽的产生。本公开涉及对治疗与β-淀粉样蛋白产生相关的神经系统疾病的化合物，如阿尔茨海默病和其他受抗淀粉样活性影响的疾病。
• Use of glycogen phosphorylase inhibitors
  申请人：——

  公开号：US20030004162A1

  公开（公告）日：2003-01-02

  The invention provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof an effective amount of a glycogen phosphorylase inhibitor; effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent. The invention further provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof a pharmaceutical composition comprising effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent.

  本发明提供了一种预防性地治疗尚未出现2型糖尿病但存在发展为该病风险的个体的方法，该方法包括向需要该方法的个体施用有效量的糖原磷酸化酶抑制剂；有效量的糖原磷酸化酶抑制剂和非糖原磷酸化酶抑制的抗糖尿病剂；或者有效量的糖原磷酸化酶抑制剂和抗肥胖剂。本发明还提供了一种预防性地治疗尚未出现2型糖尿病但存在发展为该病风险的个体的方法，该方法包括向需要该方法的个体施用包含有效量的糖原磷酸化酶抑制剂和非糖原磷酸化酶抑制的抗糖尿病剂的药物组合物；或者有效量的糖原磷酸化酶抑制剂和抗肥胖剂。
• Amino acid derived prodrugs of propofol, compositions and uses thereof
  申请人：Gallop A. Mark

  公开号：US20050004381A1

  公开（公告）日：2005-01-06

  The present invention provides propofol prodrugs, methods of making propofol prodrugs, pharmaceutical compositions of propofol prodrugs and methods of using propofol prodrugs and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as migraine headache pain and post-chemotherapy or post-operative surgery nausea and vomiting.

  本发明提供了丙泊酚前药、制备丙泊酚前药的方法、丙泊酚前药的药物组合物以及使用丙泊酚前药和药物组合物治疗或预防偏头痛疼痛、化疗后或手术后恶心和呕吐等疾病或失调的方法。
• [EN] SYNTHESIS AND CHARACTERIZATION OF SECOND GENERATION BENZOFURANONE RING SUBSTITUTED NOSCAPINE ANALOGS<br/>[FR] SYNTHÈSE ET CARACTÉRISATION D'ANALOGUES DE NOSCAPINE À CYCLE BENZOFURANONE SUBSTITUÉ DE DEUXIÈME GÉNÉRATION
  申请人：UNIV GEORGIA STATE

  公开号：WO2012171002A1

  公开（公告）日：2012-12-13

  Compounds of Formula (I) and use thereof as microtubule modulating agents in the treatment of cancer are described herein:

  本文描述了式(I)化合物及其在癌症治疗中作为微管调节剂的用途：